Urologix, Inc., based in Minneapolis, is the leading provider for in-office BPH therapy. The company develops, manufactures, markets and distributes minimally invasive medical products for BPH treatment. Urologix' Cooled ThermoTherapy™ produces targeted microwave energy combined with a unique cooling mechanism to protect healthy tissue and enhance patient comfort. The Cooled ThermoTherapy™ product line includes the CoolWave® and Targis® Control Units and the CTC Advance® and Targis® catheter families. The Prostiva® RF Therapy System distributed by Urologix delivers radio frequency energy directly into the prostate destroying prostate tissue, reducing constriction of the urethra, and thereby relieving BPH voiding symptoms. Both of these products provide safe, effective and lasting relief of the symptoms and obstruction due to BPH.
Urologix' patented Cooled ThermoTherapy™ technology is creating effective treatment options for a wide range of patients with BPH. Cooled ThermoTherapy delivers precisely targeted microwave energy that heats and destroys enlarged prostatic tissue while unique cooling mechanisms protect surrounding healthy tissue and enhances patient comfort.
Prostiva® RF Therapy provides direct visualization with 360 degrees of precision which allows the urologist to treat the median and lateral lobe as well as asymmetrical prostates. This system is able to reach intraprostatic temperatures of 110°C allowing it to create a lesion in the tissue causing significant necrosis in just two minutes and 20 seconds. Experienced physicians report good patient tolerability with the utilization of a prostate block.
Prostiva® is a registered trademark of Medtronic, Inc., used under license. All other trademarks are the property of Urologix.
¹Data on file at Urologix, Inc.
|02/04/14||Urologix Secures Extension of Credit Facility|
|Credit Line Extended Through June 30, 2014
MINNEAPOLIS, Feb. 4, 2014 (GLOBE NEWSWIRE) -- Urologix®, Inc. (OTCQB:ULGX), the leading provider of in-office procedures for the safe, durable and effective treatment of BPH, today announced that it has secured an extension to June 30, 2014 of its credit facility with Silicon Valley Bank ("SVB"), the commercial banking division of SVB Financial Group. The line of credit with SVB allows borrowing by the Company of up to the lesser of $2.0 million or the... |
|02/04/14||Urologix Reports Fiscal Year 2014 Second Quarter Results|
|Second Quarter Revenue Totaled $3.8 Million
MINNEAPOLIS, Feb. 4, 2014 (GLOBE NEWSWIRE) -- Urologix®, Inc. (OTCQB:ULGX), the leading provider of in-office procedures for the safe, durable and effective treatment of BPH, today reported financial results for its fiscal second quarter ended December 31, 2013.
Operating Results for the Second Quarter of Fiscal Year 2014
Second quarter fiscal year 2014 revenue totaled $3.8 million, up 0.7% sequentially which is relatively flat with the first... |
|01/30/14||Urologix to Host Its Fiscal Year 2014 Second Quarter Conference Call|
|MINNEAPOLIS, Jan. 30, 2014 (GLOBE NEWSWIRE) -- Urologix®, Inc. (OTCQB:ULGX) will host a conference call to present fiscal year 2014 second quarter results on Tuesday, February 4, 2014 at 4:00 p.m. CT, following the Company's post-market press release on the same day. On the day of the call, please dial 1-800-688-0836 and enter the Participant Passcode 89504173 at least 10 minutes prior to the call. The conference call will be broadcast live over the Internet at www.urologix.com. Greg Fluet, Chie... |
|01/08/14||Urologix Announces Strategic Restructuring, Reports Preliminary Revenue and Cash Results for the Second Quarter of Fiscal Year 2014|
|Second quarter revenue totaled $3.8 million, up 1% sequentially
Cash balance of $1.3M as of December 31, 2013
MINNEAPOLIS, Jan. 8, 2014 (GLOBE NEWSWIRE) -- Urologix®, Inc. (OTCQB:ULGX), the leading provider of in-office procedures for the safe, durable and effective treatment of BPH, today announced a strategic restructuring of its organization and reported preliminary financial results for its fiscal year 2014 second quarter ended December 31, 2013.
Strategic Restructuring of Sa... |
|There are currently no events scheduled.|
Receive E-mail Alerts|
|Sign up to receive e-mail alerts whenever Urologix, Inc. posts new information to the site. Just enter your e-mail address and click Submit.|